Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Amortization of Deferred Charges (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Amortization of Deferred Charges data on record, last reported at $403000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 38.75% year-over-year to $403000.0; the TTM value through Dec 2025 reached $1.7 million, down 42.89%, while the annual FY2025 figure was $1.7 million, 42.89% down from the prior year.
  • Amortization of Deferred Charges reached $403000.0 in Q4 2025 per MRVI's latest filing, up from $399000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.0 million in Q3 2021 and bottomed at -$654000.0 in Q2 2021.
  • Average Amortization of Deferred Charges over 5 years is $647150.0, with a median of $705000.0 recorded in 2022.
  • Peak YoY movement for Amortization of Deferred Charges: crashed 32800.0% in 2021, then surged 208.72% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $681000.0 in 2021, then decreased by 3.96% to $654000.0 in 2022, then rose by 13.61% to $743000.0 in 2023, then fell by 11.44% to $658000.0 in 2024, then tumbled by 38.75% to $403000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $403000.0 in Q4 2025, $399000.0 in Q3 2025, and $391000.0 in Q2 2025.